Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Liver Transplant Rejection Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Liver Transplant Rejection Overview | 8 | 1 |
| Pipeline Products for Liver Transplant Rejection Comparative Analysis | 9 | 1 |
| Liver Transplant Rejection Therapeutics under Development by Companies | 10 | 1 |
| Liver Transplant Rejection Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Liver Transplant Rejection Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Liver Transplant Rejection Products under Development by Companies | 15 | 1 |
| Liver Transplant Rejection Products under Investigation by Universities/Institutes | 16 | 1 |
| Liver Transplant Rejection Companies Involved in Therapeutics Development | 17 | 7 |
| Astellas Pharma Inc. | 17 | 1 |
| Biogen Inc | 18 | 1 |
| Conatus Pharmaceuticals Inc. | 19 | 1 |
| Digna Biotech, S.L. | 20 | 1 |
| Dompe Farmaceutici S.p.A. | 21 | 1 |
| Novartis AG | 22 | 1 |
| RedHill Biopharma Ltd. | 23 | 1 |
| Liver Transplant Rejection Therapeutics Assessment | 24 | 9 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Target | 25 | 2 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 2 |
| Assessment by Molecule Type | 31 | 2 |
| Drug Profiles | 33 | 38 |
| ABC-294640 Drug Profile | 33 | 5 |
| Cardiotrophin-1 Drug Profile | 38 | 2 |
| Cellular Immunotherapy for Liver Transplantation Drug Profile | 40 | 1 |
| Cellular Immunotherapy for Liver Transplantation Drug Profile | 41 | 1 |
| emricasan Drug Profile | 42 | 6 |
| everolimus Drug Profile | 48 | 12 |
| FX-06 Drug Profile | 60 | 2 |
| reparixin Drug Profile | 62 | 3 |
| rituximab Drug Profile | 65 | 4 |
| tacrolimus ER Drug Profile | 69 | 1 |
| TR-002 Drug Profile | 70 | 1 |
| Liver Transplant Rejection Dormant Projects | 71 | 1 |
| Liver Transplant Rejection Discontinued Products | 72 | 1 |
| Liver Transplant Rejection Product Development Milestones | 73 | 7 |
| Featured News &Press Releases | 73 | 1 |
| Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting | 73 | 1 |
| May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients | 73 | 1 |
| Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting | 74 | 1 |
| Dec 04, 2012: Astellas Pharma Announces Acceptance Of US New Drug Application For Tacrolimus Extended Release Capsules | 75 | 1 |
| Oct 20, 2011: European Medicines Agency Agrees To Precautionary Recall Of Advagraf 0.5mg Capsule Batches | 75 | 1 |
| Jul 01, 2011: Astellas Introduces Advagraf In India | 76 | 1 |
| Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I | 76 | 1 |
| Feb 18, 2011: Astellas Introduces Advagraf in China-once daily administration, leading the new trend in immunosuppressive therapy after organ transplant | 76 | 1 |
| Oct 02, 2007: New Once-Daily Advagraf Launched Across Europe. | 77 | 1 |
| Jun 18, 2007: Advagraf Now Available in Germany and the UK as a Once-Daily Immunosuppressant in Organ Transplantation | 78 | 1 |
| Apr 30, 2007: Advagraf Now Approved Across Europe as a Once-Daily Immunosuppressant in Organ Transplantation. | 79 | 1 |
| Appendix | 80 | 2 |
| Methodology | 80 | 1 |
| Coverage | 80 | 1 |
| Secondary Research | 80 | 1 |
| Primary Research | 80 | 1 |
| Expert Panel Validation | 80 | 1 |
| Contact Us | 80 | 1 |
| Disclaimer | 81 | 1 |